Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.2.0.727
Commitments and Contingencies (Details Textual)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 27, 2014
USD ($)
Mar. 31, 2015
USD ($)
Apr. 22, 2014
USD ($)
Aug. 28, 2012
USD ($)
patients
Jul. 24, 2012
USD ($)
Jun. 15, 2012
USD ($)
Dec. 31, 2007
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Sep. 30, 2014
USD ($)
Jun. 20, 2014
USD ($)
Jul. 31, 2013
USD ($)
Commitments and Contingencies (Textual)                                    
Research recorded fees               $ 3,837,959   $ 2,130,625   $ 7,886,673 $ 3,720,401          
Total project estimated to cost                                 $ 800,000  
Letter of credit     $ 34,733                              
Amount paid to goodwin                       $ 3,500,000 1,000,000          
Lease agreement description                      
On April 22, 2014, the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement expires on September 30, 2016. The Company issued a letter of credit for $34,733 to the existing tenant and maintained a $34,733 certified deposit as collateral for the letter of credit.
           
Manufacturing Agreement [Member]                                    
Commitments and Contingencies (Textual)                                    
Project estimated cost for clinical trials of drug Ac-225-HuM195 $ 1,800,000                                  
Non - refundable institutional fee 562,790                                  
Total project estimated to cost $ 3,300,000                                  
Research and development costs                       $ 200,000   $ 100,000        
Einstein [Member]                                    
Commitments and Contingencies (Textual)                                    
Research recorded fees   $ 146,713             $ 55,000   $ 0              
Total project estimated to cost                               $ 183,391    
Abbview Biotherapeutics Corp [Member] | Product Development and Patent License Agreement [Member]                                    
Commitments and Contingencies (Textual)                                    
License fee payment                       3,000,000            
Milestones payments                       $ 7,750,000            
Description of royalty payment                       The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.            
Royalty of net sales percentage                       12.00%            
Abbview Biotherapeutics Corp [Member] | After First Net Sales [Member]                                    
Commitments and Contingencies (Textual)                                    
Milestones payments                       $ 1,500,000            
Abbview Biotherapeutics Corp [Member] | Phase 1 Clinical Trial of a licensed product [Member]                                    
Commitments and Contingencies (Textual)                                    
Milestones payments         $ 750,000             750,000            
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member] | Product Development and Patent License Agreement [Member]                                    
Commitments and Contingencies (Textual)                                    
Net sales in milestones payment                       10,000,000            
Abbott Biotherapeutics Corp [Member] | Phase 1 Clinical Trial of a licensed product [Member]                                    
Commitments and Contingencies (Textual)                                    
First commercial sale period                       $ 750,000            
Aptiv Solutions [Member]                                    
Commitments and Contingencies (Textual)                                    
Down payment of project estimated cost percentage                       12.50%            
Down payment for project             $ 239,000         $ 1,900,000     $ 239,000      
Accrued expenses               200,000   200,000 $ 100,000 200,000 200,000          
Total project estimated to cost               2,700,000       2,700,000            
Fred Hutchinson Cancer Research Center [Member] | license and sponsored research agreement [Member]                                    
Commitments and Contingencies (Textual)                                    
Milestones payments           $ 1,000,000                        
Description of royalty payment           Royalty payments of 2% of net sales will be due to FHCRC.                        
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )           $ 150,000                        
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )           250,000                        
Accrued expenses               $ 169,000   $ 75,000   $ 169,000 $ 75,000          
Fred Hutchinson Cancer Research Center [Member] | Maximum [Member] | license and sponsored research agreement [Member]                                    
Commitments and Contingencies (Textual)                                    
Clinical trial cost for approval of food and drug administration           23,500,000                        
Fred Hutchinson Cancer Research Center [Member] | Minimum [Member] | license and sponsored research agreement [Member]                                    
Commitments and Contingencies (Textual)                                    
Clinical trial cost for approval of food and drug administration           $ 13,200,000                        
University of Texas M.D. Anderson Cancer Center [Member] | Clinical Trial Agreement [Member]                                    
Commitments and Contingencies (Textual)                                    
Number of Patients | patients       24                            
Amount paid to each patient after Completing clinical trial                                   $ 34,383
Start-up fee for clinical trial       $ 33,946                            
Non - refundable institutional fee       14,500                            
Total project estimated to cost       $ 500,000